Gene transfer for angiogenesis in coronary artery disease

Annual Review of Medicine

Volumn 52, Issue , 2001, Pages 485-502

  Laham, R J ^a   Simons, M ^a   Sellke, F ^a  

^a Department of Medicine   (United States)

Author keywords

Atherosclerosis; Ischemia; Local delivery; No option patients; Revascularization

Indexed keywords

ANGIOPOIETIN; COMPLEMENTARY DNA; FIBROBLAST GROWTH FACTOR; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMID VECTOR; PLATELET DERIVED GROWTH FACTOR; RECOMBINANT DNA; SCATTER FACTOR; VASCULOTROPIN;

ADENO ASSOCIATED VIRUS; ADENOVIRUS; ANGIOGENESIS; BLOOD FLOW; CLINICAL RESEARCH; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DNA VECTOR; GENE THERAPY; GENE TRANSFER; HEART MUSCLE ISCHEMIA; HUMAN; LACTOSE OPERON; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; RETROVIRUS; REVASCULARIZATION; REVIEW; SAFETY;

CORONARY DISEASE; ETHICS, MEDICAL; FORECASTING; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; PATIENT ADVOCACY; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 0035123673     PISSN: 00664219     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.med.52.1.485     Document Type: Review

References (116)

1. Utilization of coronary angiography and revascularization after acute myocardial infarction in men and women risk stratified by the American College of Cardiology/American Heart Association guidelines
2. ACC/AHA Guidelines for coronary artery bypass graft surgery: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery)
3. Electron beam computed tomography: Calcification and lipid lowering interventions
4. Importance of cardiovascular interventions before surgery for abdominal aortic aneurysms
5. Treating patients with hypertriglyceridaemia saves lives: Triglyceride revisited
6. Clinical epidemiology of acute myocardial infarction
7. Coronary atherosclerosis and interventions: Pathological sequences and restenosis
8. Controversies in primary prevention among hyperlipidemic patients
9. Importance of complete revascularization in performance of the coronary bypass operation
10. Complete and incomplete revascularization at aortocoronary bypass surgery: Experience with 392 consecutive patients
11. Growth factors as a potential new treatment for ischemic heart disease
12. Angiogenic therapy of the human heart
13. Transmyocardial laser revascularization. Does it have a role in the treatment of ischemic heart disease?
14. A review of the literature: Transmyocardial laser revascularization
15. Therapeutic angiogenesis with basic fibroblast growth factor: Technique and early results
16. Expression vector with DNA of bovine papilloma virus 1 for keratinocyte gene therapy
17. Somatic gene therapy for hypertension
18. Similar efficiency of DNA-liposome complexes and retrovirus-producing cells for HSV-tk suicide gene therapy of peritoneal carcinomatosis
19. Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity
20. Gene transfer of virally encoded chemokine antagonists vMIP-II and MC148 prolongs cardiac allograft survival and inhibits donor-specific immunity
21. Anion exchange purification of plasmid DNA using expanded bed adsorption
22. Optimisation of growth hormone production by muscle cells using plasmid DNA
23. Hepatocyte-targeted in vivo gene expression by intravenous injection of plasmid DNA complexed with syn thetic multi-functional gene delivery system
24. A novel N-acyl phosphatidylethanolamine-containing delivery vehicle for spermine-condensed plasmid DNA
25. Adenovirus-mediated E2F-1 gene transfer induces an apoptotic response in human gastric carcinoma cells that is enhanced by cyclin dependent kinase inhibitors
26. Transduction efficacy, antitumoral effect, and toxicity of adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir therapy of hepatocel lular carcinoma: The woodchuck animal model
27. Effective repeat administration with adenovirus vectors to the muscle
28. Stereotactic injection of adenoviral vectors that target gene expression to specific pituitary cell types: Implications for gene therapy
29. Genetic enhancement of matrix synthesis by articular chondrocytes: Comparison of different growth factor genes in the presence and absence of interleukin-1
30. Noninvasive measurement of gene expression in skeletal muscle
31. Gene therapy of established medullary thyroid carcinoma with herpes simplex viral thymidine kinase in a rat tumor model: Relationship of bystander effect and antitumor efficacy
32. Construction of encapsidated (gutted) adenovirus minichromosomes and their application to rescue of photoreceptor degeneration
33. Developments in gene therapy for muscular dystrophy
34. Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase
35. Adeno-associated virus site-specifically integrates into a muscle-specific DNA region
36. High throughput production, screening and analysis of adeno-associated viral vectors
37. Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium
38. Cation-exchange high-performance liquid chromatography of recombinant adenoassociated virus type 2
39. Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
40. A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation
41. Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors
42. Dose response to a single intramuscular injection of recombinant adenoassociated virus-erythropoietin in monkeys
43. Improvement of erythropoiesis in beta-thalassemic mice by continuous erythropoietin delivery from muscle
44. Design and packaging of adeno-associated virus gene targeting vectors
45. Gene transfer into stimulated and unstimulated T lymphocytes by HW-1-derived lentiviral vectors
46. Frape-1 and Frape-3: Two different recombinant retroviruses encoding the same human marker gene
47. Progress with retroviral gene vectors
48. Spleen necrosis virus-derived C-type retroviral vectors for gene transfer to quiescent cells
49. Modular retro-vectors for transgenic and therapeutic use
50. Improving gene therapy's tool kit
51. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences
52. Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo
53. Tumor-selective gene transduction and cell killing with an oncotropic autonomous parvovirus-based vector
54. Efficient cotransduction of tumors by multiple herpes simplex vectors: Implications for tumor vaccine production
55. Effect of TT virus infection on hepatocellular carcinoma development: Results of a Euro-Asian survey
56. Viral vectors for gene delivery and gene therapy within the endocrine system
57. Use of a herpes thyrnidine kinase/neomycin phosphotransferase chimeric gene for metabolic suicide gene transfer
58. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: Consequences for anti-cancer gene therapy
59. A novel endothelial cell-based gene therapy platform for the in vivo delivery of apolipoprotein E
60. Tissue-engineered human bioartificial muscles expressing a foreign recombinant protein for gene therapy
61. A gene therapy approach to regulated delivery of erythropoietin as a function of oxygen tension
62. Hematopoietic stem cell-based gene therapy for acquired immunodeficiency syndrome: Efficient transduction and expression of RevM10 in myeloid cells in vivo and in vitro
63. Vectors for cancer gene therapy
64. Endothelial cell-based cytokine gene delivery inhibits 9L glioma growth in vivo
65. Directed endothelial differentiation of cultured embryonic yolk sac cells in vivo provides a novel cell-based system for gene therapy
66. Systemic delivery of a recombinant protein by genetically modified mesothelial cells reseeded on the parietal peritoneal surface
67. Cytokine therapy with gene-transfected cells: Single injection of irradiated granulocyte-macrophage colony-stimulating factor-transduced cells accelerates hematopoietic recovery after cytotoxic chemotherapy in mice
68. Therapeutic angiogenesis in myocardial ischemia
69. Intracoronary and intravenous administration of basic fibroblast growth factor: Myocardial and tissue distribution
70. Angiogenesis in ischemic heart disease
71. Food for starving hearts
72. Myocardial perfusion in newonset angina patients with single vessel disease
73. Evolution of myocardial ischemia and left ventricular function in patients with angina pectoris without myocardial infarction and total occlusion of the left anterior descending coronary artery and collaterals from other coronary arteries
74. Vasomotor responses of newly developed coronary collateral vessels
75. Effects of antecedent anginal episodes and coronary artery stenosis on left ventricular function during coronary occlusion
76. Coronary collateral recruitment: Functional significance and relation to rate of vessel closure
77. Recent insights into coronary collateral circulation
78. The influence of angiographically demonstrated coronary collaterals on the results of stress echocardiography
79. Molecular mechanisms of collateral vessel growth
80. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia
81. Arterial gene therapy for therapeutic anglogenesis in patients with peripheral artery disease
82. 165 in a patient with ischaemic limb
83. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart
84. Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector
85. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart
86. In vivo angiogenesis induced by recombinant adenovirus vectors coding either for secreted or nonsecreted forms of acidic fibroblast growth factor
87. Thepathophysiology of the collateral circulation (arteriogenesis)
88. Transgenic mouse models in angiogenesis and cardiovascular disease
89. Vasculogenesis
90. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization
91. Angiogenesis
92. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis
93. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb
94. Tumor necrosis factor-alpha is expressed by monocytes/macrophages following cardiac microembolization and is antagonized by cyclosporine
95. Macrophage-dependent regulation of syndecan gene expression
96. PR39, a peptide regulator of angiogenesis
97. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
98. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
99. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia
100. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: Results of a phase I randomized, double-blind, placebo-controlled trial
101. Double blind placebo controlled trial of recombinant human vascular endothelial growth factor - The VIVA trial
102. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: Results of a phase I open label dose escalation study
103. 2 homeostasis by hypoxia-inducible factor 1 alpha
104. Defective vascularization of HIF-1alpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death
105. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha
106. 165 expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo
107. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor
108. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia
109. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia
110. 165 as sole therapy for myocardial ischemia
111. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease
112. 121 cDNA to individuals with clinically significant severe coronary artery disease
113. Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor
114. Protecting research subjects - What must be done
115. Is academic medicine for sale?